sintilimab monotherapy

DRUG2 trials

Sponsors

Shanghai Chest Hospital, Wang Jianliu

Conditions

Anti-angiogenesisImmunotherapyMMRd Endometrial Cancer of Stage I~IIMinimal Residual DiseaseNon-small Cell Lung Cancer

Phase 2

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

Shanghai Chest HospitalAnti-angiogenesis, Immunotherapy, Minimal Residual Disease +1

Start: 2022-01-01End: 2024-12-31Target: 42Updated: 2022-07-15

Sintilimab Monotherapy in Patients With Stage I-II MSI-H/dMMR Endometrial Cancer

Not yet recruitingNCT07731607

Wang JianliuMMRd Endometrial Cancer of Stage I~II

Start: 2026-07-20End: 2030-07-20Target: 48Updated: 2026-07-28